Table 5

Prescription of adjuvant chemotherapy according to biological type and stage. Chi square test was significant (pā€‰<ā€‰0.0001) for each biological subtype
Stage Luminal A Luminal B HER2 Triple Negative
CT yes, N (%) CT no, N (%) CT yes, N (%) CT no, N (%) CT yes, N (%) CT no, N (%) CT yes, N (%) CT no, N(%)
IA* 12 (6.0%) 187 (94.0%) 10 (30.3%) 23 (69.7%) 25 (64.1%) 14 (35.9%) 17 (81.0%) 4 (19.0%)
IB** 59 (22.6%) 202 (77.4%) 44 (50.6%) 43 (49.4%) 77 (88.5%) 10 (11.5%) 56 (100%) 0 (0%)
II*** 213 (56.2%) 166 (43.8%) 130 (76.0%) 41 (24.0%) 122 (93.1%) 9 (6.9%) 75 (100%) 0 (0%)
III**** 68 (81.0%) 16 (19.0%) 46 (90.2%) 5 (9.8%) 45 (93.8%) 3 (6.3%) 13 (100%) 0 (0%)
Total 352 (38.1%) 571 (61.9%) 230 (67.3%) 112 (32.7%) 269 (88.2%) 36 (11.8%) 161 (97.6%) 4 (2.4%)

* Stage IA: pT1mic/pT1a/pT1b and pN0 ** Stage IB: pT1c and pN0 *** Stage II: pT1 and pN1, pT2/pT3 and pN0, pT2 and pN1 **** Stage III: all pN2, all pN3, all pT4, pT3 and pN1.

Clavarezza et al.

Clavarezza et al. BMC Cancer 2012 12:216   doi:10.1186/1471-2407-12-216

Open Data